The COVID-19 pandemic continues to be a serious global health threat. Testing for the detection of SARS-CoV-2 will remain critical for managing the pandemic even during flu season. The severity of the 2020-21 flu season is uncertain as it converges with the COVID-19 pandemic.
The detection and differentiation of respiratory pathogens is important for managing patients with acute respiratory syndromes. This is even more critical during the flu season as seasonal viruses can be life-threatening, especially for hospitalized immunocompromised patients. SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) have similar clinical presentations but require different treatment approaches. Therefore, early detection and differential diagnosis may be critical for optimal patient management.
Siemens Healthineers offers a flexible combination of respiratory testing solutions for your laboratories flu season testing needs during the COVID-19 pandemic and 2020-21 flu season
FTD SARS-CoV-2 Assay* for the specific detection of the coronavirus causing COVID-19
FTD FLU/HRSV Assay** for the detection of influenza A, influenza B, and human respiratory syncytial viruses A and B
FTD Respiratory pathogens 21 Assay** for the detection of 20 viruses and 1 bacterium
Features & Benefits
- Clinically relevant kit configurations covering life-threatening circulating respiratory pathogens
- Robust assay designs showing excellent analytical and clinical performance
- Flexible kit and workflow options allowing laboratories to manage comprehensive respiratory testing
*CE-IVD labeled for diagnostic use in the EU. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner.
**CE-IVD labeled for diagnostic use in the EU. Not for diagnostics use in the USA